Coho Partners Ltd. Sells 21,945 Shares of Kenvue Inc. $KVUE

Key Points

• Coho Partners Ltd. has reduced its stake in Kenvue Inc. by 10.6%, selling 21,945 shares during the 2nd quarter, leaving it with 185,008 shares valued at approximately $3.87 million.
• Multiple analysts have lowered their price targets for Kenvue, with JPMorgan Chase reducing its target from $24.00 to $21.00, while UBS lowered theirs from $23.00 to $17.00, reflecting a generally cautious outlook.
• Kenvue recently declared an increased quarterly dividend of $0.2075, translating to an annualized rate of $0.83 and a yield of 5.9%, despite a high dividend payout ratio of 112.16%.

Coho Partners Ltd. lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 10.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 185,008 shares of the company's stock after selling 21,945 shares during the quarter. Coho Partners Ltd.'s holdings in Kenvue were worth $3,872,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of KVUE. Vanguard Group Inc. grew its holdings in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the last quarter. Third Point LLC bought a new position in shares of Kenvue in the first quarter worth about $213,422,000. Maverick Capital Ltd. bought a new position in Kenvue in the 1st quarter worth about $203,036,000. Nuveen LLC bought a new position in Kenvue in the 1st quarter worth about $187,123,000. Finally, Voya Investment Management LLC grew its stake in Kenvue by 131.3% in the 1st quarter. Voya Investment Management LLC now owns 12,131,468 shares of the company's stock worth $290,557,000 after acquiring an additional 6,886,784 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $24.00 to $21.00 and set an "overweight" rating on the stock in a research note on Friday, October 10th. UBS Group dropped their price objective on Kenvue from $23.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 8th. Zacks Research raised Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a research report on Tuesday. Finally, Barclays dropped their price target on Kenvue from $20.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $21.18.

Kenvue Stock Down 13.6%

Shares of NYSE KVUE opened at $14.05 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $26.96 billion, a PE ratio of 18.99, a price-to-earnings-growth ratio of 2.34 and a beta of 0.72. The stock's fifty day simple moving average is $18.66 and its two-hundred day simple moving average is $21.12. Kenvue Inc. has a 12-month low of $14.05 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the company earned $0.32 earnings per share. The firm's revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.9%. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio (DPR) is 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.